Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
FOXP3
REST API REST API
Homo sapiens
FOXP3 is differentially expressed in 156 experiments: 82 organism parts: lung, prostate, ... (80 more);, 141 disease states: normal, breast carcinoma, ... (139 more);, 55 cell types 165 cell lines 19 compound treatments and 71 other conditions.
Synonyms DIETER, IPEX, XPID, PIDX, JM2, AIID, SCURFIN
Orthologs FKH2 (Saccharomyces cerevisiae)   Foxp3 (Mus musculus)   FOXP3 (Bos taurus)   foxp3b (Danio rerio)   FKH1 (Saccharomyces cerevisiae)   Foxp3 (Rattus norvegicus)   FOXP3 (Xenopus laevis)   FOXP3 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term pattern specification process, embryo development, negative regulation of transcription, DNA-dependent, protein binding, regulation of transcription, DNA-dependent, cytoplasm, double-stranded DNA binding, intracellular, negative regulation of cell proliferation, protein complex, transcription, DNA-dependent, transcription corepressor activity, metal ion binding, DNA bending activity, histone deacetylase binding, sequence-specific DNA binding, positive regulation of transcription from RNA polymerase II promoter, positive regulation of histone acetylation, nucleus, protein heterodimerization activity, chromatin remodeling, transcription factor complex, post-embryonic development, histone acetyltransferase binding, chromatin binding, protein homodimerization activity, negative regulation of transcription from RNA polymerase II promoter, regulation of transcription from RNA polymerase II promoter, positive regulation of transcription, DNA-dependent, zinc ion binding, T cell receptor signaling pathway, myeloid cell homeostasis, negative regulation of interferon-gamma biosynthetic process, regulation of isotype switching to IgG isotypes, negative regulation of NF-kappaB transcription factor activity, positive regulation of CD4-positive, CD25-positive, alpha-beta regulatory T cell differentiation, cerebellum development, negative regulation of CREB transcription factor activity, negative regulation of histone acetylation, regulation of immunoglobulin production, positive regulation of regulatory T cell differentiation, tolerance induction, T cell activation, negative regulation of interleukin-2 production, negative regulation of cytokine secretion, response to virus, negative regulation of interleukin-5 production, B cell homeostasis, negative regulation of interferon-gamma production, negative regulation of inflammatory response, negative regulation of interleukin-10 production, negative regulation of interleukin-4 production, negative regulation of activated T cell proliferation, CD4-positive, CD25-positive, alpha-beta regulatory T cell differentiation, negative regulation of interleukin-6 production, NF-kappaB binding, T cell homeostasis, positive regulation of T cell tolerance induction, negative regulation of cytokine biosynthetic process, negative regulation of tumor necrosis factor production, negative regulation of interleukin-2 biosynthetic process, regulatory T cell differentiation, negative regulation of lymphocyte proliferation, negative regulation of chronic inflammatory response, positive regulation of peripheral T cell tolerance induction, negative regulation of isotype switching to IgE isotypes, tolerance induction to self antigen, positive regulation of T cell anergy, cytokine production, negative regulation of T cell proliferation, negative regulation of immune response, T cell mediated immunity, sequence-specific DNA binding transcription factor activity, negative regulation of T cell cytokine production, NFAT protein binding, negative regulation of histone deacetylation, negative regulation of sequence-specific DNA binding transcription factor activity, positive regulation of immature T cell proliferation in thymus, positive regulation of transforming growth factor beta1 production, sequence-specific distal enhancer binding RNA polymerase II transcription factor activity
InterPro Term TF_fork_head
UniProt Accession B7ZLG1, Q9BZS1, B9UN80
Gene-Disease Assocation IMMUNODYSREGULATION, POLYENDOCRINOPATHY, AND ENTEROPATHY, X-LINKED;, DIABETES MELLITUS, INSULIN-DEPENDENT; IDDM
Search EB-eye ENSG00000049768
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-AFMX-5, E-MTAB-24, E-MTAB-25, E-TABM-145, ... (14 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, E-GEOD-22639, E-GEOD-2450, ... (17 experiments)

Factor Value U/D Experiments
MCF-7
2
E-GEOD-20081, E-GEOD-19639
BC1
1
E-MTAB-37
Met5A
1
E-GEOD-6013
A375
1
1
E-MTAB-37
NCIH630
1
E-MTAB-37
NCIH1437
1
E-MTAB-37
159 more value(s).


Cell type

studied in E-GEOD-22373, E-GEOD-3920, E-MEXP-750, E-GEOD-20677, E-GEOD-13909, ... (28 experiments)

Factor Value U/D Experiments
stromal cell
2
E-GEOD-10797, E-GEOD-1460
monocyte
2
E-GEOD-11755, E-GEOD-22373
CD34+
2
1
E-AFMX-5
iPSC derived from hASC using minicircle reprogramming vector
1
E-GEOD-20033
n/a
1
E-MTAB-24
CXCR5(lo)ICOS(int) CD4 T cell
1
E-MEXP-750
49 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-6872, E-GEOD-1869, E-MEXP-2069, E-GEOD-16363, ... (34 experiments)

Factor Value U/D Experiments
lung adenocarcinoma
3
E-MTAB-37, E-MTAB-62, E-MEXP-231
Lung adenocarcinoma, gemcitabine treated, gemcitabine resistant
1
E-MTAB-62
control
1
E-GEOD-16363
colorectal adenocarcinoma
1
E-MTAB-62
FKRP mutation
1
E-GEOD-3307
no atrial fibrillation
1
E-GEOD-2240
135 more value(s).


Compound treatment

studied in E-MEXP-1601, E-MEXP-1269, E-GEOD-3284, E-GEOD-5824, E-MEXP-1335, ... (11 experiments)

Factor Value U/D Experiments
placebo
1
E-MEXP-1335
dimethyl sulfoxide
1
E-GEOD-5824
actinomycin D
2
1
E-GEOD-6400
vanadium pentoxide
1
E-GEOD-5339
unknown
1
E-GEOD-7307
anti-CD3 antibody (clone:OKT3)
1
1
E-MEXP-1601
13 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
1
E-GEOD-19519
tunicamycin
1
1
E-GEOD-19519


Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21374, E-GEOD-21589, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-21374, E-GEOD-21589, E-GEOD-16363 ... (5 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-4667, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-21887

Environmental stress
studied in E-GEOD-1643

Epiregulin elisa conc ng ml
studied in E-GEOD-5851

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-GEOD-7578, E-MTAB-108

Genotype
studied in E-TABM-1029, E-GEOD-22056, E-GEOD-3494, E-GEOD-17476

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-20540

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-MEXP-2069, E-TABM-666, E-GEOD-19519, ... (18 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-MEXP-561

Injury
studied in E-GEOD-19743

Ki67 ihc
studied in E-GEOD-21653

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Organism
studied in E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-GEOD-2004, E-LGCL-5

Phenotype
studied in E-GEOD-1657

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Progression free survival of days
studied in E-GEOD-5851

Protocol type
studied in E-GEOD-19445, E-GEOD-19246, E-GEOD-1343

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-10797

RNAi
studied in E-MEXP-1509, E-MEXP-101, E-GEOD-3697

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Treatment
studied in E-GEOD-22152, E-GEOD-19246, E-GEOD-12198

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4271, E-GEOD-4922

Processing time: 0.238 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM